Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in active ankylosing spondylitis
NCT00910273Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Jul 2009
- Primary completion
- Oct 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Etanercept with Placebo (2 arms). Primary endpoint: Flow-Mediated Dilatation at 12 weeks. Started Jul 2009; status: terminated.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00910273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00910273.